Infant Bacterial Therapeutics AB (publ), (IBT) Delårsrapport 1 januari – 30 juni 2018
August 16, 2018 02:00 ET
|
Infant Bacterial Therapeutics AB
VD kommenterar Årets andra kvartal har präglats av ett intensivt arbete med att förbereda den planerade fas III – studien, kallad ”The Connection Study”. Våra erfarenheter från den...
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – June 30, 2018
August 16, 2018 02:00 ET
|
Infant Bacterial Therapeutics AB
Message from the CEO The second quarter was dominated by extensive preparatory work relating to the pivotal phase III study, called “The Connection Study”. Our experience from the completed phase...
IBT planerar att starta fas 3 studien under andra halvåret 2018 och kontrakterar CRO
June 26, 2018 02:00 ET
|
Infant Bacterial Therapeutics AB
IBT har tidigare kommunicerat planen att initiera studien första halvåret 2018. Förberedelserna för studien har tagit något längre än beräknat och företaget planerar nu påbörja studien under andra...
IBT plans to start its phase 3 study in the second half of 2018 and contracts CRO
June 26, 2018 02:00 ET
|
Infant Bacterial Therapeutics AB
IBT has previously announced its plan to start the phase 3 study in the first half of 2018. Preparations for the study have taken slightly longer than expected and the Company now plans to initiate...
Årsstämma i Infant Bacterial Therapeutics AB
May 15, 2018 12:00 ET
|
Infant Bacterial Therapeutics AB
På årsstämman i Infant Bacterial Therapeutics AB (publ) den 15 maj, 2018 beslöts bland annat följande: fastställande av årsredovisningenbeviljad ansvarsfrihet för styrelseledamöter och...
Annual General Meeting of Infant Bacterial Therapeutics AB
May 15, 2018 12:00 ET
|
Infant Bacterial Therapeutics AB
The Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 15, 2018 voted to approve the following resolutions: Adoption of the annual reportDischarge from liability granted for the...
Update: Infant Bacterial Therapeutics AB (publ), (IBT) Delårsrapport 1 januari – 30 mars 2018
May 15, 2018 03:47 ET
|
Infant Bacterial Therapeutics AB
VD kommenterar Under fjolåret passerade IBT de viktigaste milstolparna i bolagets historia. Bolagets läkemedelskandidat, IBP-9414, vilken vi tror kommer att förebygga nekrotiserande...
Update: Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – March 30, 2018
May 15, 2018 03:47 ET
|
Infant Bacterial Therapeutics AB
Message from the CEO During the past year, IBT passed the most important milestones in the company's history. The company's drug candidate, IBP-9414, which we believe will prevent necrotizing...
Infant Bacterial Therapeutics AB (publ), (IBT) Delårsrapport 1 januari – 30 mars 2018
May 15, 2018 02:00 ET
|
Infant Bacterial Therapeutics AB
VD kommenterar Under fjolåret passerade IBT de viktigaste milstolparna i bolagets historia. Bolagets läkemedelskandidat, IBP-9414, vilken vi tror kommer att förebygga...
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – March 30, 2018
May 15, 2018 02:00 ET
|
Infant Bacterial Therapeutics AB
Message from the CEO During the past year, IBT passed the most important milestones in the company's history. The company's drug candidate, IBP-9414,...